| Company/Division name | Genentech |
| Parent company | Roche Group |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Total number of jobs (added or to be added): | 150 |
| Year reshoring announced: | 2023 |
| Year reshoring implemented or to be implemented: | 2025 |
| Capital investment ($): | 450 |
| Country(ies) from which reshored: | Switzerland |
| City reshored to: | Oceanside |
| State(s) reshored to: | CA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | biotech |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Infrastructure, Manufacturing/engineering joint innovation (R&D), Proximity to customers/market, Skilled workforce availability/training |
